Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts

NCT00159822 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00159822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00159822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Completed
Start date
July 31, 2005
Completion date
December 31, 2008
Enrollment
48 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

aspergillosis